RESULTS: A total of 93 lymph node stations were sampled in 39 patients by 10 physicians with 40 needles. All 40 evaluation forms were returned and subsequently analyzed. The needles were used in the following locations: 72.5% were used to sample station 7, 57.5% in 4R, 30.0% in 11R, 25.0% in 4L, 17.5% in tumors, 15.0% in 11L, 5.0% in 2R, 2.5% in 2L, 2.5% in 10L, 2.5% in 10R, and 2.5% in 11Ri. There were no complications. For relative performance, when asked “Did the device collect adequate samples?,” physicians graded the sample collected by the Flex 19G needle as comparable or better on 80% of forms. In response to the question, “Did the device penetrate the targets?” 75% of the forms indicated comparable or better results. To the question, “Was the device visible during sampling?” 75% of the forms provided comparable or better results. For absolute performance, physicians rated the ability of the device to collect samples, its ability to penetrate, and its visibility as acceptable 95%, 90%, and 97% of the time respectively.